Andrew Baum
Stock Analyst at Citigroup
(3.16)
# 913
Out of 4,667 analysts
58
Total ratings
77.27%
Success rate
21.76%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $55 → $60 | $58.23 | +3.04% | 10 | Nov 12, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $26.40 | +51.52% | 2 | Oct 25, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $140 → $130 | $99.86 | +30.18% | 11 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $171.73 | +25.20% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $675 → $895 | $749.92 | +19.35% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $12.44 | -19.61% | 3 | Oct 20, 2023 | |
| PFE Pfizer | Maintains: Neutral | $42 → $35 | $25.13 | +39.28% | 9 | Oct 16, 2023 | |
| GSK GSK | Downgrades: Neutral | n/a | $33.70 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Neutral
Price Target: $55 → $60
Current: $58.23
Upside: +3.04%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $26.40
Upside: +51.52%
Merck & Co.
Oct 25, 2024
Maintains: Buy
Price Target: $140 → $130
Current: $99.86
Upside: +30.18%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $171.73
Upside: +25.20%
Eli Lilly
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $749.92
Upside: +19.35%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $12.44
Upside: -19.61%
Pfizer
Oct 16, 2023
Maintains: Neutral
Price Target: $42 → $35
Current: $25.13
Upside: +39.28%
GSK
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $33.70
Upside: -